AGIOS PHARMACEUTICALS INC (AGIO)
US00847X1046 - Common Stock
AGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
AGIO stock results show that Agios Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Agios Reports Business Highlights and First Quarter 2024 Financial Results
– Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2...
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation...
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now.
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024...
Notable Monday Option Activity: BOOM, GT, AGIO
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024...
Agios Pharmaceuticals GAAP EPS of -$6.33 misses by $0.07, revenue of $26.82M misses by $0.9M (NASDAQ:AGIO)
Agios Pharmaceuticals reports Q4 2023 financial results, with a missed GAAP EPS by $0.07 and revenue of $26.82M missing by $0.9M.
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Agios reports fourth quarter and full year 2023 financial results and recent business highlights...
Bullish Two Hundred Day Moving Average Cross - AGIO
7 Biotech Stocks Fighting America’s Deadliest Diseases
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.
AIM stock dips amid mixed results for post-COVID fatigue therapy (NASDAQ:AGIO)
AIM ImmunoTechn (AIM) stock dipped after the company reported mixed topline results from a Phase 2 study of Ampligen for post-COVID fatigue. Read more here.
Investors growing more bullish on SMID cap biotech stocks (NASDAQ:ALNY)
Investors are more bullish about small and mid-cap biotech stocks this year, with Merus (MRUS) and Fusion (FUSN) viewed as most likely to outperform, according to TD Cowen.
Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024
CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering...
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
– Industry-leading PK Activator Franchise Has Demonstrated Clinical Efficacy in Four Hematological Diseases, Including New Positive Phase 3 Data in...
CRISPR, bluebird stocks slide as Agios rallies on thalassemia study (NASDAQ:AGIO)
Shares of CRISPR (CRSP) and bluebird bio (BLUE) were trading significantly lower Wednesday afternoon after Agios Pharmaceuticals (AGIO) announced positive Phase
Agios Pharma Surges, And Retakes Its 200-Day Line, On Promising Test Results For Thalassemia Drug
The company is working on an oral treatment for alpha and beta thalassemia.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers with all of the latest coverage worth reading about on Wednesday morning!
Agios stock rallies after mitapivat meets key goal in thalassemia trial (NASDAQ:AGIO)
Agios Pharmaceuticals shares surge as late-stage trial of mitapivat shows promising results for thalassemia treatment, paving the way for potential...
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
–Mitapivat Demonstrated a Statistically Significant Increase in Hemoglobin Response Rate Compared to Placebo – – Statistical Significance Also Achieved...
Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering...
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition...
Commit To Purchase Agios Pharmaceuticals At $15, Earn 3.7% Using Options
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence;One Study Patient Achieved Hemoglobin Response Endpoint – – Safety Profile...
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition
– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease,...
Agios Pharmaceuticals GAAP EPS of -$1.64 beats by $0.06, revenue of $7.4M misses by $0.13M (NASDAQ:AGIO)
Agios Pharmaceuticals reports Q3 earnings, beating earnings per share estimates but missing revenue expectations.
Agios Reports Business Highlights and Third Quarter 2023 Financial Results
– First Patient Dosed in Phase 3 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease – – Completed Enrollment in Phase 3...
Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023
Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023...
Relative Strength Alert For Agios Pharmaceuticals
Noteworthy Monday Option Activity: MU, AGIO, AMR
Commit To Buy Agios Pharmaceuticals At $22.50, Earn 10.4% Annualized Using Options
Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering...
Notable Monday Option Activity: ASPN, TH, AGIO
(NASDAQ:AGIO)
Agios Pharmaceuticals press release (AGIO): Q2 GAAP EPS of -$1.51 beats by $0.05.Revenue of $6.7M (+116.1% Y/Y) beats by $0.24M. Cash, cash equivalents and marketable securities as...
Agios Reports Business Highlights and Second Quarter 2023 Financial Results
Announced Positive Results from Phase 2 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease; On Track to Enroll First Patient in Phase...